Hüseyin Kadioğlu1, Serap Yücel2, Seyma Yildiz3, Süleyman Bozkurt4, Yeliz Emine Ersoy4, Esra Sağlam2, Mahmut Müslümanoğlu4. 1. Department of General Surgery, Bezmialem Vakıf Üniversitesi, Tıp Fakültesi Hastanesi, Fatih/Istanbul 34083, Turkey. Electronic address: huseyinkadioglu@gmail.com. 2. Department of Radiation Oncology, Bezmialem Vakıf Üniversitesi, Fatih/Istanbul, Turkey. 3. Department of Radiology, Bezmialem Vakıf Üniversitesi, Fatih/Istanbul, Turkey. 4. Department of General Surgery, Bezmialem Vakıf Üniversitesi, Tıp Fakültesi Hastanesi, Fatih/Istanbul 34083, Turkey.
Abstract
BACKGROUND: Multifocal breast cancers (MFBCs) present a challenge to surgeons. Although its feasibility is still controversial, breast-conserving surgery (BCS) is not contraindicated for MFBCs. The investigators retrospectively evaluated the feasibility of BCS and reviewed histopathologic findings in patients with MFBC. METHODS: A total of 222 patients with MFBC who were treated with either BCS (119 patients) or mastectomy (103 patients) at a single institution between January 2002 and December 2011 were retrospectively evaluated. RESULTS: The median follow-up time was 55 months (range, 10 to 102 months). Lymphovascular invasion and lymph node involvement were significantly less frequent in the BCS group (48.8% vs 62.2% for lymphovascular invasion, P = .04; 52.1% vs 71.8% for lymph node involvement, P = .002). There were no differences in local recurrence rates between the 2 groups. The overall survival rates were 92% in the BCS group and 72% in the mastectomy group (P = .000). CONCLUSIONS: BCS is a feasible and safe procedure for the removal of multifocal tumors. Extended lymphovascular invasion is associated with mortality in patients who undergo mastectomy.
BACKGROUND: Multifocal breast cancers (MFBCs) present a challenge to surgeons. Although its feasibility is still controversial, breast-conserving surgery (BCS) is not contraindicated for MFBCs. The investigators retrospectively evaluated the feasibility of BCS and reviewed histopathologic findings in patients with MFBC. METHODS: A total of 222 patients with MFBC who were treated with either BCS (119 patients) or mastectomy (103 patients) at a single institution between January 2002 and December 2011 were retrospectively evaluated. RESULTS: The median follow-up time was 55 months (range, 10 to 102 months). Lymphovascular invasion and lymph node involvement were significantly less frequent in the BCS group (48.8% vs 62.2% for lymphovascular invasion, P = .04; 52.1% vs 71.8% for lymph node involvement, P = .002). There were no differences in local recurrence rates between the 2 groups. The overall survival rates were 92% in the BCS group and 72% in the mastectomy group (P = .000). CONCLUSIONS: BCS is a feasible and safe procedure for the removal of multifocal tumors. Extended lymphovascular invasion is associated with mortality in patients who undergo mastectomy.
Authors: Z E Winters; J Horsnell; K T Elvers; A J Maxwell; L J Jones; A M Shaaban; P Schmid; N R Williams; A Beswick; R Greenwood; J C Ingram; C Saunders; J S Vaidya; L Esserman; I Jatoi; A M Brunt Journal: BJS Open Date: 2018-05-22